Theravectys

Institut Pasteur

Centre National De La Recherche Scientifique

Other

Ludwig Institute for Cancer Research Limited

Inserm

Ixaka France

Cecile Bauche

Claude Leclerc

Daniel Ladant

Nicole Guiso

Mohammed El-Azami El-Idrissi

Pierre Guermonprez

Pierre Charneau

Renaud Vaillant

Emeline Sarry

Catherine Fayolle

Nadia Khelef

Deborah Revaud

Thi-Lan Tran

Gael Ouengue Mbele

Philippe Bishop

Benoit Van Den Eynde

Gilles Dadaglio

Sandra Morel

Methods of making lyophilized lentiviral vector particles are provided. Compositions comprising lyophilized lentiviral vector particles are also provided. Methods of administering a lentiviral vector particle to a subject and uses of lentiviral vector particle compositions are also provided.

Lyophilized lentiviral vector particles, compositions and methods

The invention relates to a novel use of aadenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.

Vectors for molecule delivery to CD11b expressing cells

The present invention relates to compositions, methods, and uses employing lentiviral vector particles for induction of an immune response by administration to a human, wherein the lentiviral vector particles comprise a lentiviral vector, wherein the DNA of the lentiviral vector comprises a promoter directing expression of a HTLV-1 p12p30-Tax-HBZ fusion protein. The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.

Lentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1

The invention encompasses a lentiviral packaging vector comprising a non-subtype B gag-pol sequence, particularly a subtype D gag-pol sequence. The invention further encompasses methods for making and using these vectors. The invention further encompasses lentiviral vector particles comprising HIV-1 non-subtype B Gag and/or Pol proteins.

Use of non-subtype B gag proteins for lentiviral packaging

The present invention relates to the insertion of an MHC class I, MHC Class II, or &#x3b2;2 microglobulin upstream promoter sequence into a lentiviral vector to increase viral titers. The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.

Lentiviral vectors containing an MHC class I, MHC class II, or B2 microglobulin upstream promoter sequence

The present invention relates to the insertion of a promoter sequence from an MHC class I gene promoter into a lentiviral vector in order to direct the transcription of a transgene, which preferably encodes an immunogenic polypeptide to be expressed in a mammalian cell host, preferably APC (DCs). The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.

Lentiviral vectors containing an MHC class I promoter

Growing community of inventors

Paris, France

Cecile Bauche